Integrated Ventures Inc (INTV): I did so well in this stock both in 2017...

nwsun · 2025-02-06T00:16:19.9770000Z

I did so well in this stock both in 2017/2018 and 2020/2021. It's sad to see it falter like it is.. Is it even producing anything at this time? When I first bought in it was some kind of medical service, then RS and became a miner. Sometimes I wonder if these supposed OTC business models are real or exist only in narrative and are part of a nefarious agenda. The whole penny stock market seems to be languishing as though it's being destroyed intentionally.

Play Episode

12min

Proactive - Interviews for investors

Graphene Manufacturing CEO on fuel savings & expansion

Graphene Manufacturing Group Ltd CEO Craig Nicol talked with Proactive about the company's latest performance testing results for G®LUBRICANT, a graphene-based engine oil additive. Nicol explained that testing conducted with the University of Queensland has demonstrated an 8.5% fuel efficiency improvement in high-load conditions. He highlighted that the additive works by reducing friction in the engine, allowing for better lubrication and fuel economy. “Thirty percent of your fuel is wasted due to piston friction, and our product addresses that issue,” Nicol stated. The interview also covered GMG’s commercial rollout strategy, initially targeting the B2B trucking market in Australia before expanding into larger diesel fuel markets globally. Nicol emphasized that truck owners could save approximately $8,000 per year in fuel costs by using the additive. Additionally, Nicol discussed GMG’s partnership with the Battery Innovation Center of Indiana to advance graphene aluminum-ion battery development. He noted that the company recently secured a $5 million capital raise to support product commercialization, expand production capacity, and explore a potential U.S. stock exchange listing. For more updates on Graphene Manufacturing Group Ltd, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future content. #GrapheneManufacturingGroup #Graphene #FuelEfficiency #GMG #Lubricants #EnergySavings #DieselEngines #BatteryTech #Innovation #SustainableEnergy #Investing

Proactive - Interviews for investors

Sona Nanotech CMO discusses THT's potential to enhance immunotherapy efficacy

Sona Nanotech Inc chief medical officer Dr Carman Giacomantonio takes Proactive's Stephen Gunnion through the company’s latest findings related to its targeted hyperthermia therapy (THT), which he described as showing “very enabling immunogenic” effects in recent experiments. The THT platform works by delivering controlled heat to the core of a tumour, triggering a natural cell death response and activating the body's immune system. Giacomantonio explained that this process exposes tumour proteins to immune cells, increasing the chance that they will be recognised and attacked. He noted that “all cancer cells have this kind of evolutionary quality” of resisting cell death, but THT stresses the cells enough to induce it. These latest experiments build on data first shared in December, with increased sample sizes confirming the reproducibility of the results. According to Giacomantonio, tumours treated with saline or checkpoint inhibitors alone continued to grow, while those exposed to THT and the immune modulator PD1 showed complete inhibition or reduction in growth. Looking ahead, he said the company plans to expand testing to demonstrate systemic immune responses, with the goal of treating metastatic cancers by targeting a single tumour site. Visit Proactive's YouTube channel for more company updates. Don’t forget to give this video a like, subscribe to the channel, and enable notifications so you never miss future content. #SonaNanotech #CancerTherapy #TargetedHyperthermia #Immunotherapy #BiotechNews #TumourTreatment #CancerResearch #MedicalInnovation #PD1Inhibitor #MetastaticCancer #HealthcareTech #OncologyBreakthrough

Proactive - Interviews for investors

St George Mining’s dual track growth plan

St George Mining Ltd executive chairman John Prineas talked with Kerry Stevenson at Proactive about the company's recent acquisition of the Araxá niobium and rare earths project in Brazil. The deal, completed in February, provides St George with an advanced-stage project with high-grade niobium and rare earth elements. Prineas highlighted niobium’s strategic importance, noting that it is primarily used to strengthen steel, with additional applications in medical technology, batteries, and defence. He emphasised the commodity's stable pricing due to limited global supply. The company secured A$20 million in funding to advance the project and is preparing a JORC-compliant mineral resource estimate, expected in the coming weeks. The existing data, based on historical drilling, indicates a 20-year mine life and a US$956 million NPV under a previous non-JORC study. St George aims to optimise the project for niobium, conduct further drilling, and expand the resource. Prineas also addressed Brazil's mining jurisdiction, highlighting strong government support and agreements to expedite approvals. The company is pursuing a dual-track strategy, progressing toward development while ramping up exploration drilling to expand the resource base. Stay tuned for more updates! Visit Proactive's YouTube channel for more interviews, and don’t forget to like, subscribe, and turn on notifications. #StGeorgeMining #ASXSGQ #Niobium #RareEarths #MiningStocks #JORC #BrazilMining #CriticalMetals #ResourceInvestment #BatteryMetals

Proactive - Interviews for investors

Polarean Imaging chief business officer on potential of Xenon MRI pharma trials

Polarean Imaging PLC chief business officer Alex Dusek talked with Proactive's Stephen Gunnion about the company’s latest expansion into pharmaceutical-sponsored trials. This new initiative involves a multinational trial utilising Polarean’s Xenon MRI technology to assist drug development for lung diseases. Dusek explained that traditional lung function tests, such as spirometry, are crude and highly variable, making trials costly and time-consuming. Xenon MRI offers a more sensitive measurement, reducing variability and allowing drug companies to conduct trials with significantly fewer patients. "If you're designing a trial, let's say it's 25 to 50 patients with Xenon, that would take you 250 to 500 patients with the more traditional measures," he noted. Polarean is providing pharmaceutical companies with imaging biomarkers and harmonised data analysis, streamlining drug development. The company is also establishing a network of clinical sites equipped with Xenon MRI, creating an ecosystem that benefits sponsors, trial sites, and Polarean itself. Dusek highlighted Polarean’s partnership with VIDA Diagnostics, a well-known name in lung drug development, to further enhance the impact of this initiative. For more insights into Polarean Imaging’s latest developments, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates. #PolareanImaging #XenonMRI #LungDisease #DrugDevelopment #ClinicalTrials #PharmaResearch #MedicalImaging #Biotech #HealthcareInnovation #Investing

Followers	92
Posts	26038
Boards Moderated	0
Alias Born	04/08/2005

Volume:	2,610
Day Range:	0.2329 - 0.2329
Bid:	0.2329
Ask:	0.291
Last Trade Time:	12:01:40 PM EDT
Total Trades:	8

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

INTV Detailed Quote

Recent INTV News

More INTV News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent INTV News

Go Ad-Free